Cargando…
Barriers From Third-Party Payers to Biologic Use in Pediatric Inflammatory Bowel Disease
Biologic agents are now standard of care in the treatment of inflammatory bowel disease (IBD). The ability to use biologics in clinical practice is in part dictated by insurance company policies. There is a long delay between adult and pediatric approval of biologic agents, and these therapies are o...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins, Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158370/ https://www.ncbi.nlm.nih.gov/pubmed/37168642 http://dx.doi.org/10.1097/PG9.0000000000000215 |